{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:39:55Z","timestamp":1783471195780,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000736","name":"University of East Anglia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000736","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Laboratory studies have suggested that statins may have useful anti-cancer effects against Barrett\u2019s epithelial cancer lines. A variety of effects have been reported in clinical studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a systematic review and meta-analysis of the association between statin use and the development of oesophageal cancer. Multiple databases were searched for studies reporting the association of statin use and oesophageal cancer. Meta-analysis on the relationship between statin use and cancer incidence was performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty publications met eligibility criteria, yielding 22 datasets for meta-analysis. All were observational studies. Population-level studies included 372,206 cancer cases and 6,086,906 controls. Studies examining adenocarcinoma development in Barrett\u2019s oesophagus included 1057 cancers and 17,741 controls. In patients with Barrett\u2019s oesophagus, statin use was associated with a reduced incidence of adenocarcinoma (pooled adjusted odds ratio (OR) 0.59 (95% confidence intervals 0.50\u20130.68)), with no heterogeneity between 11 studies. Population-based studies demonstrated more heterogeneity but showed that statin use was associated with a lower incidence of both oesophageal adenocarcinoma (OR 0.57 (0.43\u20130.76)) and all oesophageal cancers (OR 0.82 (0.7\u20130.88)). Information on statin type, dose, and duration was reported too infrequently for statistical analysis but individual studies showed a tendency to a dose- and duration-dependant decrease in cancer incidence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Statin use is associated with a significantly lower incidence of oesophageal adenocarcinoma. This is seen in both Barrett\u2019s cohorts and general populations. Further studies should focus on drug, dose, and duration and the interaction with other risk and preventative factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12029-017-9983-0","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T01:36:49Z","timestamp":1499650609000},"page":"442-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma"],"prefix":"10.1007","volume":"49","author":[{"given":"Tom","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon","family":"Loke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1923-3237","authenticated-orcid":false,"given":"Ian L. P.","family":"Beales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"issue":"9864","key":"9983_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400\u201312.","journal-title":"Lancet"},{"issue":"3","key":"9983_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","volume":"64","author":"M Arnold","year":"2015","unstructured":"Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381\u20137.","journal-title":"Gut"},{"issue":"22","key":"9983_CR3","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1002\/cncr.28313","volume":"119","author":"Z Wang","year":"2013","unstructured":"Wang Z, Goodman M, Saba N, El-Rayes BF. Incidence and prognosis of gastroesophageal cancer in rural, urban, and metropolitan areas of the United States. Cancer. 2013;119(22):4020\u20137.","journal-title":"Cancer"},{"issue":"34","key":"9983_CR4","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.3748\/wjg.v19.i34.5598","volume":"19","author":"Y Zhang","year":"2013","unstructured":"Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34):5598\u2013606.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"9983_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1053\/j.gastro.2011.04.061","volume":"141","author":"NJ Shaheen","year":"2011","unstructured":"Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, et al. Durability of radiofrequency ablation in Barrett\u2019s esophagus with dysplasia. Gastroenterology. 2011;141(2):460\u20138.","journal-title":"Gastroenterology"},{"issue":"4","key":"9983_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/j.1572-0241.2007.01773.x","volume":"103","author":"OO Ogunwobi","year":"2008","unstructured":"Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett\u2019s esophageal adenocarcinoma cells. Am J Gastroenterol. 2008;103(4):825\u201337.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"9983_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1749-6632.2011.06053.x","volume":"1232","author":"D Fang","year":"2011","unstructured":"Fang D, Das KM, Cao W, Malhotra U, Triadafilopoulos G, Najarian RM, et al. Barrett\u2019s esophagus: progression to adenocarcinoma and markers. Ann N Y Acad Sci. 2011;1232(1):210\u201329.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"9983_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1756283X14538689","volume":"7","author":"E Long","year":"2014","unstructured":"Long E, Beales IL. The role of obesity in oesophageal cancer development. Ther Adv Gastroenterol. 2014;7(6):247\u201368.","journal-title":"Ther Adv Gastroenterol"},{"issue":"4","key":"9983_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.4291\/wjgp.v5.i4.534","volume":"5","author":"L Alexandre","year":"2014","unstructured":"Alexandre L, Long E, Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol. 2014;5(4):534\u201349.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"suppl 3","key":"9983_CR10","first-page":"141","volume":"58","author":"PC Konturek","year":"2007","unstructured":"Konturek PC, Burnat G, Hahn EG. Inhibition of Barrett\u2019s adenocarcinoma cell growth by simvastatin: invollvment of COX-2 and apoptosis-related proteins. J Physiol Pharmacol. 2007;58(suppl 3):141\u20138.","journal-title":"J Physiol Pharmacol"},{"issue":"6","key":"9983_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.cgh.2012.12.036","volume":"11","author":"S Singh","year":"2013","unstructured":"Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett\u2019s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(6):620\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"9983_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4292\/wjgpt.v4.i3.69","volume":"4","author":"IL Beales","year":"2013","unstructured":"Beales IL, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther. 2013;4(3):69\u201379.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"9983_CR13","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"349","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.","journal-title":"BMJ"},{"issue":"7","key":"9983_CR14","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1053\/j.gastro.2010.02.045","volume":"138","author":"DM Nguyen","year":"2010","unstructured":"Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett\u2019s esophagus. Gastroenterology. 2010;138(7):2260\u20136.","journal-title":"Gastroenterology"},{"issue":"12","key":"9983_CR15","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cgh.2009.06.001","volume":"7","author":"DM Nguyen","year":"2009","unstructured":"Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett\u2019s esophagus. Clin Gastroenterol Hepatol. 2009;7(12):1299\u2013304.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"9983_CR16","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1053\/j.gastro.2011.08.036","volume":"141","author":"F Kastelein","year":"2011","unstructured":"Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett\u2019s esophagus. Gastroenterology. 2011;141(6):2000\u20138.","journal-title":"Gastroenterology"},{"key":"9983_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1158\/1055-9965.EPI-11-1014","volume":"21","author":"ED Kantor","year":"2012","unstructured":"Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett\u2019s esophagus. Cancer Epidemiol Biomark Prev. 2012;21:456\u201361.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"8","key":"9983_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1097\/MEG.0b013e3283543f01","volume":"24","author":"IL Beales","year":"2012","unstructured":"Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett\u2019s oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol. 2012;24(8):917\u201323.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"9983_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.gie.2015.12.036","volume":"84","author":"R Krishnamoorthi","year":"2016","unstructured":"Krishnamoorthi R, Borah B, Heien H, Das A, Chak A, Iyer PG. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett\u2019s esophagus cohort. Gastrointest Endosc. 2016;84(1):40\u20136.","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"9983_CR20","first-page":"S-121-S-122","volume":"146","author":"Prasad G. Iyer","year":"2014","unstructured":"Iyer PG, Borah B, Heien H, et al. Rates and predictors of progression to adenocarcinoma in a large population based Barrett\u2019s esophagus cohort. [Abstract] Gastroenterology 2014;146:S-121-2","journal-title":"Gastroenterology"},{"issue":"12","key":"9983_CR21","doi-asserted-by":"publisher","first-page":"774","DOI":"10.14423\/SMJ.0000000000000212","volume":"107","author":"S Agrawal","year":"2014","unstructured":"Agrawal S, Patel P, Agrawal A, Makhijani N, Markert R, Deidrich W. Metformin use and the risk of esophageal cancer in Barrett esophagus. South Med J. 2014;107(12):774\u20139.","journal-title":"South Med J"},{"issue":"1","key":"9983_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006640","volume":"5","author":"GM Masclee","year":"2015","unstructured":"Masclee GM, Coloma PM, Spaander MC, Kuipers EJ, Sturkenboom MC. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett\u2019s oesophagus: a population-based case-control study. BMJ Open. 2015;5(1):e006640.","journal-title":"BMJ Open"},{"issue":"2","key":"9983_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/2050640614523596","volume":"2","author":"S Cooper","year":"2014","unstructured":"Cooper S, Menon S, Nightingale P, Trudgill NJ. Risk factors for the development of oesophageal adenocarcinoma in Barrett\u2019s oesophagus: a UK primary care retrospective nested case-control study. United European Gastroenterol J. 2014;2(2):91\u20138.","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"9983_CR24","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1053\/j.gastro.2015.07.009","volume":"149","author":"T Nguyen","year":"2015","unstructured":"Nguyen T, Duan Z, Naik AD, Kramer JR, El-Serag HB. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett\u2019s esophagus: a nested case-control study. Gastroenterology. 2015;149(6):1392\u20138.","journal-title":"Gastroenterology"},{"issue":"3","key":"9983_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/sj.bjc.6601566","volume":"90","author":"JA Kaye","year":"2004","unstructured":"Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90(3):635\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"9983_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/pds.1507","volume":"17","author":"GD Friedman","year":"2008","unstructured":"Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008;17(1):27\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9983_CR27","doi-asserted-by":"publisher","first-page":"c2197","DOI":"10.1136\/bmj.c2197","volume":"340","author":"J Hippisley-Cox","year":"2010","unstructured":"Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.","journal-title":"BMJ"},{"key":"9983_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/1471-2407-11-409","volume":"11","author":"Y Vinogradova","year":"2011","unstructured":"Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011;11:409.","journal-title":"BMC Cancer"},{"issue":"Suppl 2","key":"9983_CR29","doi-asserted-by":"publisher","first-page":"A299.2-A300","DOI":"10.1136\/gutjnl-2012-302514d.8","volume":"61","author":"H Y Bhutta","year":"2012","unstructured":"Bhutta HY, Alexandre L, Clark A, et al. Do statins prevent the histological subtypes of oesophageal cancer? Prospective data from the UK General Practice Database (GPRD). [Abstract] Gut 2012;61 (Suppl 2):A299\u2013300","journal-title":"Gut"},{"key":"9983_CR30","doi-asserted-by":"publisher","first-page":"18830","DOI":"10.3402\/ljm.v7i0.18830","volume":"7","author":"S Lai","year":"2012","unstructured":"Lai S, Liao K, Lai H, Muo C, Sung F. Atorvastatin correlates with decreased risk of esophageal cancer: a population-based case-control study from Taiwan. Libyan J Med. 2012;7:18830.","journal-title":"Libyan J Med"},{"issue":"3","key":"9983_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1517\/14740338.2013.778241","volume":"12","author":"TF Chan","year":"2013","unstructured":"Chan TF, Chiu HF, Wu CH, Lin CL, Yang CY. Statin use and the risk of esophageal cancer: a population-based case-control study. Expert Opin Drug Saf. 2013;12(3):293\u20138.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"9983_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1053\/j.gastro.2013.11.046","volume":"146","author":"L Alexandre","year":"2014","unstructured":"Alexandre L, Clark AB, Bhutta HY, Holt S, Lewis MP, Hart AR. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. Gastroenterology. 2014;146(3):661\u20138.","journal-title":"Gastroenterology"},{"key":"9983_CR33","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1442-2050.2012.01412.x","volume":"26","author":"I Beales","year":"2013","unstructured":"Beales I, Vardi I, Dearman L, Broughton T. Statin use is associated with a reduction in the incidence of esophageal adenoncarcinoma: a case-control study. Dis Esophagus. 2013;26:838\u201346.","journal-title":"Dis Esophagus"},{"issue":"15","key":"9983_CR34","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008\u201312.","journal-title":"JAMA"},{"key":"9983_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10620-015-3869-4","volume":"61","author":"IL Beales","year":"2016","unstructured":"Beales IL, Dearman L, Vardi I, Loke Y. Reduced risk of Barrett\u2019s esophagus in statin users: case-control study and meta-analysis. Dig Dis Sci. 2016;61:238\u201346.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"9983_CR36","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1136\/gutjnl-2013-305997","volume":"63","author":"S Singh","year":"2014","unstructured":"Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett\u2019s oesophagus: a systematic review and meta-analysis. Gut. 2014;63(8):1229\u201337.","journal-title":"Gut"},{"issue":"15","key":"9983_CR37","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1056\/NEJMoa1103042","volume":"365","author":"F Hvid-Jensen","year":"2011","unstructured":"Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett\u2019s esophagus. N Engl J Med. 2011;365(15):1375\u201383.","journal-title":"N Engl J Med"},{"key":"9983_CR38","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/gutjnl-2011-300730","volume":"61","author":"TK Desai","year":"2012","unstructured":"Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett\u2019s oesophagus: a meta-analysis. Gut. 2012;61:970\u20136.","journal-title":"Gut"},{"issue":"4","key":"9983_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1365-2036.2007.03582.x","volume":"27","author":"P Moayyedi","year":"2008","unstructured":"Moayyedi P, Burch N, Akhtar-Danesh N, Enaganti SK, Harrison R, Talley NJ, et al. Mortality rates in patients with Barrett\u2019s oesophagus. Aliment Pharmacol Ther. 2008;27(4):316\u201320.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-017-9983-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-017-9983-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-017-9983-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:52:02Z","timestamp":1628599922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-017-9983-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["9983"],"URL":"https:\/\/doi.org\/10.1007\/s12029-017-9983-0","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]},"assertion":[{"value":"10 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The datasets analysed during the current study are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}